Clinical Benefits of First-Line (1L) Cemiplimab Monotherapy by PD-L1 Expression Levels in Patients With Advanced NSCLC


Kilickap S., Sezer A., Gumus M. , Bondarenko I., Ozguroglu M., Gogishvili M., ...More

JOURNAL OF THORACIC ONCOLOGY, vol.16, no.3, 2021 (Journal Indexed in SCI) identifier

  • Publication Type: Article / Abstract
  • Volume: 16 Issue: 3
  • Publication Date: 2021
  • Title of Journal : JOURNAL OF THORACIC ONCOLOGY